Kaneka Probiotics (Newark, CA) will be holding a webinar for the dietary supplements industry. Dr. Robert Barry will outline the unique hypolipidemic attributes of specific, clinically-tested KABP probiotic strains. The company will also cover published experimental and clinical data demonstrating lipid reductions and mechanisms of action. The webinar is made available for scientific exchange activities only and not for the commercial promotion of the products discussed.
Dietary supplements for cholesterol/lipid reduction have long utilized a core group of familiar nutrients including sterols, omega-3s, tocotrienols, soluble fibers, pantethine and polymethoxylated flavonoids. Today, there is yet another potent option for the reduction of lipids and improvement in cardiovascular health: a multi-strain, Lactobacillus plantarum KABP formulation known as “Floradapt Cardio.”
Register for this webinar to learn about Floradapt Cardio Probiotic, a three-strain L. plantarum formulation consisting of KABP-011, KABP-012 and KABP-013, and its recent journal publications. In the most recent study, Floradapt Cardio demonstrated the ability to reduce serum LDL cholesterol and TG regardless of age, gender or specific medications. Furthermore, the study noted that higher lipid reductions were observed on subjects with high baseline cholesterol levels.
Floradapt Cardio reduces endogenous and exogenous cholesterol and increases triglyceride expenditure through multiple mechanisms of action. These mechanisms include increased bile salt hydrolase activity and short chain fatty acid production (SCFAs). Register for this webinar to learn about the evidence of gut microbiota for improving cardiovascular health.
Join Robert J. Barry, PhD, executive director of scientific affairs, Kaneka, for the live webinar on Wednesday, April 28, 2021 at 11 a.m. EDT (4 p.m. BST/U.K.).
For more information, visit https://xtalks.com/webinars/reduction-of-blood-lipids-a-new-era-for-cardiovascular-formulations/.
